Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
DUBLIN–(BUSINESS WIRE)–Feb. 12, 2026– Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avade...
Wake Up Narcolepsy (WUN) is a 501(c)(3) nonprofit organization dedicated to driving Narcolepsy awareness, education and research towards improved treatments and a cure.
Narcolepsy by the Numbers
2000
Narcolepsy affects 1 in every 2,000 Americans and 3 million people worldwide.
50
It is estimated that up to 50% of patients with Narcolepsy may be undiagnosed.
20
Typical onset of Narcolepsy is between the ages of 10 and 20 years old, but can occur in early childhood.
6
On average, patients have 6 physician visits before receiving a Narcolepsy diagnosis.
Online Support GroupsFree, online support groups worldwide for people with Narcolepsy and their families. |
National SummitThis one-day summit is for people with Narcolepsy, their families, educators, clinicians and researchers. |
Clinical TrialsPatient engagement in clinical trials help find new ways to treat individuals with Narcolepsy. |
Annual Family WeekendChildren & Teens with Narcolepsy can meet others experiencing the same symptoms and challenges. |
Join Our TeamDo you share our passion for advocating on behalf of those with Narcolepsy? |
What’s New?
-
-
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
OSAKA, Japan and CAMBRIDGE, Massachusetts, February 10, 2026 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S.......
-
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
DUBLIN–(BUSINESS WIRE)–Jan. 6, 2026– Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) ha...
-
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net....